Drugs / JNJ-64511070
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03693391 | Oct 2018 → Mar 2019 | — | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64511070 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03693391 ↗ |
| Known as | [18F]JNJ-64511070 | “An Open-Label Study to Investigate the AMPAɣ8 Receptor Occupancy of JNJ-64140284 With the Newly Developed TARP-γ8 PET Tracer [18F]JNJ-64511070 in Healthy Men” NCT03693391 ↗ |
| Modality | Diagnostic / imaging agent | “TARP-γ8 PET tracer [18F]JNJ-64511070” NCT03693391 ↗ |
| Route | Intravenous | “An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.” NCT03693391 ↗ |